681 related articles for article (PubMed ID: 30499317)
1. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
[TBL] [Abstract][Full Text] [Related]
2. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone.
Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z
World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617
[TBL] [Abstract][Full Text] [Related]
3. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius.
Abuhejleh H; Wunder JS; Ferguson PC; Isler MH; Mottard S; Werier JA; Griffin AM; Turcotte RE
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):11-17. PubMed ID: 31297594
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the risk factors for local recurrence of giant cell tumor of long bone].
Xu H; Niu X
Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):465-8. PubMed ID: 25241792
[TBL] [Abstract][Full Text] [Related]
6. Does pathological fracture affect the rate of local recurrence in patients with a giant cell tumour of bone?: a meta-analysis.
Salunke AA; Chen Y; Chen X; Tan JH; Singh G; Tai BC; Khin LW; Puhaindran ME
Bone Joint J; 2015 Nov; 97-B(11):1566-71. PubMed ID: 26530662
[TBL] [Abstract][Full Text] [Related]
7. [Surgical treatment for long bone giant cell tumor of extremity with pathologic fracture].
Li X; Guo W; Yang Y; Wei R; DU ZY
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):745-51. PubMed ID: 24136271
[TBL] [Abstract][Full Text] [Related]
8. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
9. Giant cell tumour of bone.
Aoude A; Nikomarov D; Perera JR; Ibe IK; Griffin AM; Tsoi KM; Ferguson PC; Wunder JS
Bone Joint J; 2023 May; 105-B(5):559-567. PubMed ID: 37121582
[TBL] [Abstract][Full Text] [Related]
10. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.
Campanacci L; Sambri A; Medellin MR; Cimatti P; Errani C; Donati DM
Acta Orthop Traumatol Turc; 2019 Sep; 53(5):376-380. PubMed ID: 31253385
[TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of giant cell tumors with pathological fracture around the knee].
Liu WF; Yang FJ; Li Y; Li B; Hao L; Niu XH
Zhonghua Wai Ke Za Zhi; 2018 Sep; 56(9):677-686. PubMed ID: 30157574
[No Abstract] [Full Text] [Related]
12. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
14. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
[TBL] [Abstract][Full Text] [Related]
15. Giant cell tumour of bone in the appendicular skeleton: an analysis of 276 cases.
Xing R; Yang J; Kong Q; Tu C; Zhou Y; Duan H
Acta Orthop Belg; 2013 Dec; 79(6):731-7. PubMed ID: 24563982
[TBL] [Abstract][Full Text] [Related]
16. Extended curettage versus en bloc resection for the treatment of grade 3 giant cell tumour of the knee with pathologic fracture: a retrospective study.
Jamshidi K; Zandrahimi F; Haji Agha Bozorgi M; Arefpour AM; Bagherifard A; Al-Baseesee HH; Mirzaei A
Int Orthop; 2021 Jan; 45(1):289-297. PubMed ID: 33001283
[TBL] [Abstract][Full Text] [Related]
17. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
18. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
19. Giant cell tumor with pathologic fracture: should we curette or resect?
van der Heijden L; Dijkstra PD; Campanacci DA; Gibbons CL; van de Sande MA
Clin Orthop Relat Res; 2013 Mar; 471(3):820-9. PubMed ID: 22926445
[TBL] [Abstract][Full Text] [Related]
20. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
